Doctor of Philosophy (University of Texas Health Science Center at Houston & MD Anderson Cancer Center)

Master of Science (Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences)

Bachelor of Science (Sichuan University)

Professor Wenchu Lin graduated from Sichuan University in 1996 and obtained his master’s degree from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. He then received his doctorate from University of Texas Health Science Center at Houston & MD Anderson Cancer Center in 2006. Before joining High Magnetic Field Laboratory of Chinese Academy of Sciences as a principal investigator in Dec, 2012, he conducted postdoctoral researches at M D Anderson Cancer Center and Harvard Medical School & Dana-Farber Cancer institute from 2006 to 2012 and worked as a research scientist II at Harvard Medical School & Dana-Farber Cancer institute in 2012 after the completion of his postdoc training. He joined The Chinese University of Hong Kong, Shenzhen in 2023.

Dr. Wenchu Lin has been engaging in cancer research for 23 years with special focus on the molecular mechanisms involved in cancer progression and metastasis and roles of epigenetic regulators in cancers. Dr. Wenchu Lin has published more than 61 papers in internationally renowned academic journals, including Cell, PNAS, Molecular Cancer, Cancer discovery, Journal of Pathology, Matter, ACS Nano, etc. The published papers have been cited more than 2400 times.

Selected Publications

1. Jiahui Zhang#, Xiaoli Liu, Peng Hou, Yang Lv, Gongfeng Li, Guozhen Cao, Huogang Wang, Wenchu Lin*. BRCA1 orchestrates the response to BI-2536 and its combination with alisertib in MYC-driven small cell lung cancer. Cell Death & Disease. 2024 15:551. (corresponding authorship)
2. Yong Qian^#, Jinglu Zou^#, Jiahui Zhang^#, Xingyu Wanga,b, Xiangfu Menga, Yefeng Lina,b, Wenchu Lin*, Miqin Zhang*, and Hui Wang*. Structural Engineering of Magnetite Nanozymes for Enhanced Chemodynamic Cancer Therapy. Chemical Engineering Journal. 2024 490:151867. (co-corresponding authorship) (IF:～15.1)
3. Hongji Liu^#, Zhiming Deng, Zonghui Zhang, Wenchu Lin*, Miqin Zhang,* Hui Wang*. Graphene quantum dots as metal-free nanozymes for chemodynamic therapy of cancer. Matter. 2024 Mar 6;7(3):977–990. (co-corresponding authorship) (IF:～18.9)
4. Xiangfu Meng^#, Zonghui Zhang^#, Yong Qian, Xingyu Wang, Yefeng Lin, Xinyi Shi, Wenchu Lin*, Miqin Zhang*, and Hui Wang*. Carbon-encapsulated magnetite nanodoughnut as a NIR-II responsive nanozyme for synergistic chemodynamic–photothermal therapy. Adv. Healthcare Mater. 2023 Aug 8:e2301926. (co-corresponding authorship) (IF:～10)
5. Guozhen Cao^#, Liying Ma, Zonghui Zhang, Xiaolin Wang, Jinghan Hua, Jiahui Zhang, Yang Lv, Shaobo Zhang, Jian Ou, Wenchu Lin*. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors. Acta Pharmacologica Sinica. 2023 Apr;44(4):841-852. (corresponding authorship)  (IF:～7.17)  
6. Yefeng Lin^#, Ke Zhou^#, Shaobo Zhang^#, Yijun Lu, Yuan He, Hongji Liu, Xiangfu Meng, Yong Qian, Xingyu Wang, Xinyi Shi, Wenchu Lin*, Junchao Qian*, Hui Wang*. NIR-II Responsive Carbon Coated Magnetite Nanoclusters for Magnetic Resonance Imaging-Guided Photothermalenhanced Chemodynamic Therapy. 2023. Science China-Materials. 2023 Mar 31; 66(6):2492-2503. (co-corresponding authorship) (IF:～8.64)
7. Xiaolin Wang^#, Jiahui Zhang, Guozhen Cao, Jinghan Hua, Ge Shan*, Wenchu Lin*. Emerging roles of circular RNAs in gastric cancer metastasis and drug resistance. Journal of Experimental & Clinical Cancer Research. 2022 Jul 11;41(1):218.  (co-corresponding authorship) (IF:～12.66)
8. Jinghan Hua^#, Xiaolin Wang^#, Liying Ma, Jingxin Li, Guozhen Cao, Shaobo Zhang, Wenchu Lin*. CircVAPA promotes small cell lung cancer progression by modulating the miR-377-3p and miR-494-3p/IGF1R/AKT axis. Molecular Cancer. 2022 Jun 6, 21(1):123. (corresponding authorship) (IF:～37.3)  
9. Xiaolin Wang^#, Jinghan Hua, Jingxin Li, Jiahui Zhang, Emmanuel Enoch Dzakah, Guozhen Cao, Wenchu Lin*. Mechanisms of non-coding RNA-modulated alternative splicing in cancer. RNA Biology. 2022. 19(1):541-547. (corresponding authorship) (IF:～4.77)  
10. Yanping Yin^#, Liying Ma^#, Guozhen Cao, Jinghan Hua, Xiaotong Lv, Wenchu Lin*. FK228 potentiates topotecan activity against small cell lung cancer cells via induction of SLFN11. Acta Pharmacologica Sinica. 2022 Aug;43(8):2119-2127. (corresponding authorship)  (IF:～7.17)  
11. Yong Qian^#, Jiahui Zhang^#, Jinglu Zou^#, Xingyu Wang, Xiangfu Meng, Hongji Liu, Yefeng Lin, Qianwang Chen, Lei Sun*, Wenchu Lin*, and Hui Wang*. NIR-II responsive PEGylated nickel nanoclusters for photothermal enhanced chemodynamic synergistic oncotherapy. Theranostics. 2022 May 1;12(8):3690-3702. (co-corresponding authorship) (IF:～11.6)  
12. Yang Lv^# , Xiaotong Lv^#, Jiahui Zhang, Guozhen Cao, Changzhi Xu, Buchang Zhang, Wenchu Lin*. BRD4 targets the KEAP1-Nrf2-G6PD axis and suppresses redox metabolism in small cell lung cancer. Antioxidants. 2022 Mar 29;11(4):661. (corresponding authorship) (IF:～7.67)  
13. Xiaolin Wang^#, Jingxin Li^#, Xing Bian, Cheng Wu, Jinghan Hua, Shuhui Chang, Tianyi Yu, Hong Li, Yongxiang Li, Shanshan Hu*, Ge Shan*, Wenchu Lin*. CircURI1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer. Proceedings of the National Academy of Sciences of the United States of America. 2021 Aug 17; 118 (33) e2012881118. (co-corresponding authorship, lead contact) (IF: ～12.78)
14. Xingyu Wang^#, Changwei Li^#, Junchao Qian^#, Xiaotong Lv, Hong Li, Jinglu Zou, Jiahui Zhang, Xiangfu Meng, Hongji Liu, Yong Qian, Wenchu Lin*, and Hui Wang*. NIR-II Responsive Hollow Magnetite Nanoclusters for Targeted Magnetic Resonance Imaging-Guided Photothermal/Chemo-Therapy and Chemodynamic Therapy. Small. 2021 Aug;17(31):e2100794. (co-corresponding authorship) (IF: ～15.15)
15. Yanping Yin^#, Wenhao Shi^#, Ke Deng, Xiaoli Liu, Hong Li, Xiaotong Lv, Vivian Wai Yan Lui, Chen Ding*, Bo Hong*, Wenchu Lin*. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer. Acta Pharmacologica Sinica. 2021 Aug;42(8):1298-1310. (co-corresponding authorship, lead contact) (IF:～7.17)  
16. Hong Li^#, Liying Ma^#, Xing Bian, Yang Lv, Wenchu Lin*. FK228 sensitizes radioresistant small cell lung cancer cells to radiation. Clinical Epigenetics. 2021 Feb 25;13(1):41. (corresponding authorship) (IF:～7.26)
17. Liying Ma^#, Xing Bian^#, Wenchu Lin*. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.  Journal of Experimental & Clinical Cancer Research. 2020 Oct 17;39(1):219. (corresponding authorship) (IF:～12.66)
18. Hongji Liu^#, Xiaotong Lv^#, Junchao Qian^#, Hong Li, Yong Qian, Xingyu Wang, Xiangfu Meng, Wenchu Lin*, Hui Wang*. Graphitic carbon nitride quantum dots embedded in carbon nanosheets for near-infrared imaging-guided combined photo-chemotherapy. ACS Nano. 2020 Oct 27;14(10):13304-13315. (co-corresponding authorship) (IF:～18.03)  
19. Ao Xu^#, Wei Wang^#, Jinfu Nie, Vivian WY Lui, Bo Hong*, Wenchu Lin*. Germline mutation and aberrant transcripts of WWOX gene in syndrome with multiple primary tumors. Journal of Pathology. 2019 Sep; 249(1):19-25. (co-corresponding authorship, lead contact) (IF:～9.88)  
20. Wenchu Lin^#, Jian Cao^#, Jiayun Liu,….., Matthew Meyerson*, William G. Kaelin, Jr.*, and Qin Yan. Loss of the RBP2 histone demethylase suppresses tumorigenesis in mouse models of Rb1 and Men1 tumor suppressor gene inactivation. Proceedings of the National Academy of Sciences of the United States of America.  2011 Aug 16; 108(33): 13379-86. (IF:～10.50)